Want to see NKTR full AI Analyst Report?
NKTR Stock Chart & Stats
$70.72
$0.30(0.42%)
At close: 4:00 PM EDT
$70.72
$0.30(0.42%)
Day’s Range― - ―
52-Week Range$27.87 - $109.00
Previous CloseN/A
Volume103.19K
Average Volume (3M)1.06M
Market Cap
$2.56B
Enterprise Value$1.76K
Total Cash (Recent Filing)$684.34M
Total Debt (Recent Filing)$135.93M
Price to Earnings (P/E)―
Beta3.52
Next Earnings
Nov 05, 2026EPS Estimate
-2.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.70
Shares Outstanding34,142,994
10 Day Avg. Volume732,604
30 Day Avg. Volume1,060,557
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)7.94
Price to Sales (P/S)12.91
P/FCF Ratio-3.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$143.43Price Target Upside102.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-8.23
Revenue Forecast (FY)$41.96M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And RunwayThe substantial cash balance funds pivotal development and operating needs through key 2028 readouts, reducing near-term financing pressure. This provides flexibility to advance the pipeline while management works toward potential commercialization.
Pipeline Advancing Into Phase 3Progression into pivotal trials is a meaningful development milestone that could convert rezpeg from a research asset into a commercial product. FDA-aligned designs also clarify the path toward future regulatory submissions in large autoimmune markets.
Durable Clinical Differentiation PotentialDeep responses, durability after treatment, and a favorable reported safety profile could differentiate rezpeg if reproduced in Phase 3. These attributes may support adherence, maintenance dosing, and adoption in chronic inflammatory diseases.
Bears Say
Large Ongoing Cash BurnNektar remains dependent on its cash balance and future financing or partnering because operations consume substantial cash. Continued Phase 3 investment could accelerate burn, limiting flexibility if development timelines extend or capital markets weaken.
Contracting And Concentrated RevenueThe current revenue base is small, declining, and primarily tied to royalty income rather than internally marketed products. This leaves Nektar without dependable operating revenue to offset rising development costs before rezpeg can potentially launch.
Long, Execution-dependent Path To ApprovalValue creation depends on multi-year Phase 3 execution, positive efficacy and safety outcomes, regulatory approval, and eventual market adoption. The runway reaches key AD data but offers limited buffer for delays, added spending, or trial setbacks.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was $27.87 and its highest was $109.00 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $2.56B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 70 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Aug 13, 2026. The company reported -$1.23 earnings per share for the quarter, beating the consensus estimate of -$1.971 by $0.741.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -2.13.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 34,142,994 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$1.23 in its last earnings report, beating expectations of -$1.971. Following the earnings report the stock price went down -3.82%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in NKTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$143.43 (102.81% Upside)
$143.43 (102.81% Upside)
Blogger Sentiment
Bullish
NKTR Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 443.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $85.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
187.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
427.69%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
NKTR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call contained multiple substantial positive developments: initiation of the global Phase 3 program in atopic dermatitis, FDA-aligned registrational design for alopecia areata, strong Phase 2b signals (efficacy, durability, favorable safety), robust cash balance after a $350M offering, and encouraging market research supporting commercial potential. Offsetting these positives are expected higher R&D and G&A spend, a meaningful quarterly net loss, modest near-term revenue largely from non-cash royalties, a cash runway that covers key mid-2028 readouts but leaves limited buffer for delays, and an ongoing litigation matter. On balance the strategic, clinical, and financial highlights outweigh the risks described on the call.View all NKTR earnings summariesNKTR Stock 12 Month Forecast
Average Price Target
$143.43
▲(102.81% Upside)
Technical Analysis
Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
2.95% Insiders
13.67% Mutual Funds
48.30% Other Institutional Investors
22.91% Public Companies and
Individual Investors